The company's high P/S ratio is backed by strong forecasted ...

Moomoo AI Mar 16, 2024 07:04

The company's high P/S ratio is backed by strong forecasted revenue growth, outpacing the rest of the Pharmaceuticals industry. Investors anticipate this growth, justifying a higher stock price. A significant share price drop is unlikely under these conditions.

Market Participants Recognise Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Revenues Pushing Shares 26% Higher

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

5932 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4878

Followers

Following

11K

Visitors